Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination

Bristol-Myers Squibb Company (NYSE:BMY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 3, Arcus Biosciences announced a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Company (NYSE:BMY), where Arcus’s investigational kidney cancer drug, casdatifan, will be added to Bristol-Myers’s ongoing Phase 1/2 ROSETTA RCC-208 trial. The trial focuses on pumitamig, an investigational bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb targeting patients with advanced renal cell carcinoma (RCC).

Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination

Arcus said that it will supply casdatifan for use in two new treatment arms that will be added to the existing ROSETTA RCC-208 trial structure. However, both companies retain full development and commercial rights to their respective drugs.

Arcus CEO Terry Rosen, Ph.D., noted that this collaboration with Bristol-Myers is strategic and that it is “a top priority for Arcus in order to potentially deliver an additional effective TKI-free option in the first-line setting.”

Separately, on June 8, Bristol-Myers launched “Investigating Myeloma”, a multiple myeloma awareness campaign in partnership with actress and advocate Mariska Hargitay. Hargitay is best known for her 27-year run as Detective Olivia Benson on Law & Order: SVU, and she lost her father to the disease 20 years ago.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, immunology, cardiovascular, and neuroscience.

READ NEXT: 10 Best Stocks to Buy Now for Good Returns and 10 Best Growth Stocks to Buy According to Billionaire Dan Loeb.

Disclosure: None. Follow Insider Monkey on Google News.